Xspray Pharma Targets Q4 2026 NDA Resubmissions for Dasynoc and Nilopki

Xspray plans to resubmit NDAs for its drugs Dasynoc and Nilopki in the fourth quarter of 2026. The FDA has confirmed that these resubmissions can proceed independently of NerPharMa's cGMP status, though final FDA facility clearance for NerPharMa is still required before approval.